Age threshold for anticoagulation in patients with atrial fibrillation: A Swedish nationwide observational study

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Controversy exists regarding anticoagulant use in atrial fibrillation (AF) patients with low stroke risk.
• Determining the appropriate age cut-off for anticoagulant treatment initiation is debated.

Purpose of the Study:

• To investigate the efficacy and safety of anticoagulant therapy in AF patients across different age groups and risk strata.
• To evaluate the association between anticoagulant therapy and the incidence of cerebral infarction and cerebral bleeding.

Main Methods:

• Retrospective nationwide cohort study using Swedish National Patient Register and Prescribed Drugs Register.
• Inclusion of AF patients diagnosed between July 2005 and December 2014.
• Analysis of age categories (<55, 55-59, 60-64, 65-74 years) and CHA2DS2-VA scores (0 and 1), employing Cox regression for outcome associations.

Main Results:

• Anticoagulant therapy was associated with reduced cerebral infarction incidence in all age categories above 55 years compared to no therapy.
• Hazard ratios for cerebral infarction decreased with age and higher CHA2DS2-VA scores, ranging from 0.72 (55-59 years, score 0) to 0.37 (65-74 years, score 1).
• Increased risk of cerebral bleeding was observed in three specific categories: <55 years (score 0), 55-59 years (score 1), and 65-74 years (score 1).

Conclusions:

• Anticoagulant therapy should be considered for atrial fibrillation patients aged 55 years and older, even in the absence of other stroke risk factors.
• The findings support a potential benefit of anticoagulation in older AF patients, balancing stroke prevention against bleeding risk.